A story of evolution and achievement
Our journey began in 1997 and, from day one, Biolab has been committed to promoting greater health and well-being for people, providing quality of life through medicines. Our trajectory is marked by innovations that make a difference and by the relentless pursuit of evolution in health.
Our veterinary division, Avert® Animal Health, took an important step in 2023 by acquiring Petitos®. Now, under the management of Avert®, it has become Pet Nutrition® and has centralized the production and distribution of the snack lines, guaranteeing Biolab quality in every product.
In 2022, we took a big step by acquiring Exzell Pharma, a Canadian pharmaceutical company. This acquisition strengthens our global presence and provides us with an international platform for exporting our products. This expansion reinforces our commitment to innovative, high-quality healthcare solutions.
In 2020, we began construction of the manufacturing complex in Pouso Alegre, Minas Gerais, a significant milestone in our history. This strategic investment not only expands our production capacity but also enhances our ability to reach even more people with essential healthcare.
We have expanded our portfolio of medicines for the Central Nervous System (CNS) area in order to meet the growing demand for mental health. Our ongoing commitment is to offer complete therapeutic solutions in line with the progressive needs of society.
In 2019, we introduced the ID.Biolab range, comprising a series of vitamin and mineral supplements aimed at promoting longevity and well-being. With a wide variety of products, our range aims to help people lead healthier and more fulfilling lives.
In 2018, we took another significant step towards increasing access to medicines in the Brazilian market. We decided to enter the generics sector by acquiring the portfolio of Actavis Farmacêutica Ltda.
We took an important step in 2017 by establishing a pioneering international Research, Development and Innovation (RD&I) center in Mississauga, Canada. This initiative has allowed us to work with international experts in search of solutions to promote global health and well-being.
In 2014, we founded Avert® Biolab Saúde Animal, with a focus on pet health. This initiative reflects our ongoing commitment to the care and quality of life of the whole family, including veterinary care for our dogs and cats.
In 2013, we followed a new chapter of growth and innovation with the acquisition of our Bragança Paulista plant, in the interior of the state of São Paulo. This manufacturing expansion has allowed us to meet the growing demand for our products and continue our commitment to innovation and the development of solutions to improve people's lives.
The collaboration between Biolab and the German company Merz in 2010 led to the Merz-Biolab joint venture, which expanded our international expansion and opened up new business opportunities. This cooperation allowed us to launch the Procedures line and introduce Xeomin® botulinum toxin to our portfolio, strengthening our presence in the therapeutic market.
In 2008 we acquired the Jandira (SP) plant, strengthening our production of oral and non-hormonal solids. In 2018, the manufacturing structure was expanded to also produce soft capsules and sachets, in order to offer the practicality and benefits of these presentations to our consumers as well.
In cooperation with the University of São Paulo (USP), we developed Vonau Flash®, a leading anti-emetic in medical areas such as Pediatrics and Gastroenterology, which benefits more than 6 million patients a year. This partnership propels us globally, with exports to countries such as Ecuador and Colombia, and has already generated more than R$ 30 million in royalties for the university, which represents 90% of the total received by the educational institution, which in turn reinvests the value to generate more health for the Brazilian population.
In 1999 we opened our Research, Development and Innovation (RD&I) center in Itapecerica da Serra (SP). Now, focused on innovation and the development of our own products, we mark the beginning of a new era at Biolab Sanus Farmacêutica Ltda.
With the acquisition of our first factory in Taboão da Serra (SP), we began producing solid, semi-solid and injectable medicines, both hormonal and non-hormonal. That same year saw the launch of the drug Aradois, a milestone in cardiology and one of the most respected and prescribed drugs for heart care in Brazil.